Licensed disease modifying drugs
Clinical trials have shown that disease modifying drugs (DMDs) reduce the number of MS relapses by around a third over two years.
Find out more about:
For a more in-depth look at DMDs see our booklet Disease modifying drugs.
Beta interferon and glatiramer acetate
These drugs are injected. Clinical trials have shown the drugs reduce the number of relapses by around a third over two years.
Tysabri
Tysabri is given as a monthly infusion into a vein for people with more 'aggressive' MS, or people who have had an increase in the number or severity of relapses while taking one of the other disease modifying drugs.
Gilenya
Gilenya is an oral tablet. It was licensed in the UK for the treatment of rapidly evolving relapsing remitting MS in April 2011.
